HTR5A is a human gene. This page covers the gene's normal function, disease associations, expression patterns, and key research findings relevant to neurodegeneration.
The HTR5A gene encodes the 5-hydroxytryptamine receptor 5A (also known as 5-HT5A), a G protein-coupled receptor (GPCR) that binds serotonin (5-hydroxytryptamine or 5-HT) as its endogenous ligand. The 5-HT5A receptor is one of the least characterized serotonin receptor subtypes, yet it plays important roles in neural development, sleep architecture, and cognitive processes.
| Attribute | Value |
|---|---|
| Gene Symbol | HTR5A |
| Official Full Name | 5-hydroxytryptamine receptor 5A |
| Chromosomal Location | 7q36.3 |
| Gene ID | 3363 |
| UniProt ID | P30939 |
| Protein Class | G protein-coupled receptor, Family 5-HT |
The 5-HT5A receptor is a seven-transmembrane domain GPCR that couples primarily to Gαi/o proteins, leading to inhibition of adenylate cyclase and reduced cyclic AMP (cAMP) production. This receptor is expressed predominantly in the central nervous system (CNS), with highest expression in the cerebral cortex, hippocampus, hypothalamus, and raphe nuclei.
Upon serotonin binding, 5-HT5A receptor activation triggers the following intracellular signaling cascades:
In the brain, 5-HT5A receptors are localized to:
This distribution suggests roles in mood regulation, memory consolidation, circadian rhythm control, and motor coordination.
The 5-HT5A receptor plays a critical role in sleep-wake cycling. Studies in knockout mice demonstrate that HTR5A deletion results in:
The receptor's expression in the suprachiasmatic nucleus links it to circadian rhythm regulation.
Evidence from animal models suggests involvement in:
5-HT5A antagonists have been shown to enhance certain forms of memory in preclinical studies.
While less studied than other serotonin receptors (5-HT1A, 5-HT2A), the 5-HT5A receptor is implicated in:
Although not a primary disease-causing gene, HTR5A variations may modify disease progression in:
Alzheimer's Disease (AD):
Parkinson's Disease (PD):
Schizophrenia:
Major Depressive Disorder:
The 5-HT5A receptor has been implicated in seizure susceptibility. Animal studies show that 5-HT5A agonists have anticonvulsant properties, while antagonists may lower seizure thresholds.
| Drug Class | Examples | Clinical Use |
|---|---|---|
| Agonists | LSD, 5-CT | Research only |
| Antagonists | SB-699929, AS-203 | Under investigation |
| Mixed agents | Various atypical antipsychotics | Schizophrenia, bipolar disorder |
Pharmaceutical companies have shown interest in 5-HT5A ligands for:
Several single nucleotide polymorphisms (SNPs) in HTR5A have been studied:
Genetic association studies have linked HTR5A variants to:
The 5-HT5A receptor interacts with:
Protein Partners:
Cross-talk Pathways:
The HTR5A gene encodes an important but understudied serotonin receptor with roles in sleep regulation, cognitive function, and mood. While not a primary driver of neurodegeneration, understanding 5-HT5A function may reveal:
Further research is needed to fully characterize this receptor's functions and therapeutic potential.